HBM Holdings Limited (2142.HK)

1.410 -0.060 (-4.08%) At close: 04:08PM HKT

HBM Holdings Limited

Building A3
Suite 202 218 Xinghu Street Suzhou Industrial Park
Suzhou 215123
China
86 51 2657 90025
https://www.harbourbiomed.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 177

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Jingsong Wang M.D., Ph.D.	Founder, Chairman & CEO	7.24M	N/A	1965
Dr. Yiping Rong Ph.D.	Chief Scientific Officer & Executive Director	3.05M	N/A	1978
Mr. Weihao Xu	CFO, Chief Business Officer and Global Head of Business & Corporate Development	N/A	N/A	1983
Mr. Bruce Zhang	Head of Legal	N/A	N/A	N/A
Dr. Peter F. Moesta Ph.D.	Member of Scientific Advisory Board & Chief CMC Advisor	N/A	N/A	N/A
Dr. Xiaolu Tao	Chief Development Officer	N/A	N/A	1974
Dr. Steve Arkinstall DPhil	Chief Scientific Advisor	N/A	N/A	N/A
Mr. Wing Yat Lui	Company Secretary	N/A	N/A	1990

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. The company has developed the Harbour Mice Platform, which generates fully human monoclonal antibodies in the classical two heavy and two light chain H2L2 and heavy chain formats. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; HBM7008, a bispecific antibody targeting tumor Associated antigen; HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4; and HBM1020, human monoclonal antibody generated from harbour mice platform targeting B7H7. The company is also developing HBM9378 for the treatment of Asthma; and HBM1007, HBM1022, HBM7022, HBM9027, HBM9033, HBM7004, HBM1047, and HBM9014 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaborations with AstraZeneca, Pfizer, Hualan Genetic Engineering Co., Ltd., Beigene, Ltd., Duality Biotherapetuics, Inc., Mythic Therapeutics, Washington University, Evive Biotech. HBM Holdings Limited was incorporated in 2016 and is based in Suzhou, the People's Republic of China.

Corporate governance

HBM Holdings Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.